Related Experiment Video
Updated: Feb 8, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design
Hiroshi Wada1, Atsushi Shimizu1, Toshihiro Osada1
1Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki, Japan.
Abstract:
Recently, many autologous tumor antigens have been examined for their potential use in cancer immunotherapy. However, the success of cancer vaccines in clinical trials has been limited, partly because of the limitations of using single, short peptides in most attempts. With this in mind, we aimed to develop multivalent synthetic long peptide (SLP) vaccines containing multiple cytotoxic T-lymphocyte (CTL) epitopes. However, to confirm whether a multivalent vaccine can induce an individual epitope-specific CTL, the only viable screening strategies currently available are interferon-gamma (IFN-γ enzyme-linked immunospot (ELISPOT) assays using human peripheral blood mononuclear cells, or expensive human leukocyte antigen (HLA)-expressing mice. In this report, we evaluated the use of our developed murine-20S immunoproteasome (i20S) digestion assay, and found that it could predict the results of IFN-γ ELISPOT assays. Importantly, the murine-i20S digestion assay not only predicted CTL induction, but also antitumor activity in an HLA-expressing mouse model. We conclude that the murine-i20S digestion assay is an extremely useful tool for the development of "all functional" multivalent SLP vaccines.
Insights
A new murine assay predicts the effectiveness of multivalent cancer vaccines. This tool helps develop synthetic long peptide (SLP) vaccines by identifying functional cytotoxic T-lymphocyte (CTL) epitopes, improving cancer immunotherapy outcomes.
Area of Science:
- Immunology
- Cancer Research
- Vaccine Development
Background:
- Autologous tumor antigens are explored for cancer immunotherapy, but clinical success is limited.
- Single, short peptides in cancer vaccines have shown restricted efficacy.
- Developing multivalent vaccines with multiple cytotoxic T-lymphocyte (CTL) epitopes is a promising strategy.
Purpose of the Study:
- To develop multivalent synthetic long peptide (SLP) vaccines containing multiple CTL epitopes.
- To establish a reliable screening method for evaluating the efficacy of multivalent SLP vaccines.
- To assess the predictive capability of a newly developed murine-20S immunoproteasome (i20S) digestion assay.
Main Methods:
- Development of multivalent synthetic long peptide (SLP) vaccines.
- Evaluation of a murine-20S immunoproteasome (i20S) digestion assay.
- Comparison of i20S assay results with interferon-gamma (IFN-γ) ELISPOT assays.
- Assessment of antitumor activity in human leukocyte antigen (HLA)-expressing mouse models.
Main Results:
- The murine-i20S digestion assay successfully predicted the outcomes of IFN-γ ELISPOT assays.
- The i20S assay demonstrated predictive power for CTL induction.
- The assay also correlated with observed antitumor activity in mouse models.
Conclusions:
- The murine-i20S digestion assay is a valuable tool for screening and developing effective multivalent SLP vaccines.
- This assay aids in identifying vaccines that induce epitope-specific CTL responses.
- The developed assay supports the creation of "all functional" multivalent SLP vaccines for cancer immunotherapy.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
11:12Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
Published on: October 4, 2017
Related Concept Videos
Vaccinations
Protein Digestion
Carbohydrate Digestion
Peptide Bonds
What is Monogastric Digestion?
Lipid Digestion